Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Clinical_Trials
|
| gptkbp:adverse_events_monitoring |
yes
|
| gptkbp:advocacy |
obtained from all participants
|
| gptkbp:analysis |
statistical analysis
|
| gptkbp:clinical_trial |
gptkb:Clinical_Trials.gov
third phase highly significant results |
| gptkbp:collaborator |
other research institutions
|
| gptkbp:collection |
clinical assessments
2017 to 2020 |
| gptkbp:condition |
psoriasis
|
| gptkbp:criteria |
history of certain infections
history of inadequate response to systemic therapy |
| gptkbp:duration |
52 weeks
|
| gptkbp:eligibility |
adults with moderate to severe plaque psoriasis
|
| gptkbp:follow-up_duration |
up to 5 years
|
| gptkbp:funding |
provided by Abb Vie
|
| gptkbp:future_prospects |
recommended for further research
|
| gptkbp:has_implications_for |
potential new treatment options
|
| gptkbp:has_limitations |
noted in final report
|
| https://www.w3.org/2000/01/rdf-schema#label |
UNCOVER-3
|
| gptkbp:identifier |
NCT03364039
|
| gptkbp:is_tested_for |
Phase 3
|
| gptkbp:location |
multiple countries
|
| gptkbp:long-term_efficacy |
assessed in follow-up studies
|
| gptkbp:participants |
approximately 1000
Dermatology Life Quality Index (DLQI) Psoriasis Area and Severity Index (PASI) score |
| gptkbp:patient_population |
varied ethnic backgrounds
|
| gptkbp:patient-reported_outcomes |
assessed during trial
|
| gptkbp:prevention |
gptkb:risankizumab
|
| gptkbp:primary_investigator |
lead researcher name
|
| gptkbp:provides_information_on |
available upon request
|
| gptkbp:publication |
results published in medical journals
|
| gptkbp:publication_year |
gptkb:2021
|
| gptkbp:regulatory_compliance |
gptkb:FDA
|
| gptkbp:related_products |
gptkb:risankizumab
|
| gptkbp:research_focus |
treatment of psoriasis
|
| gptkbp:research_output |
improved quality of life for patients
improved skin clearance |
| gptkbp:result |
demonstrated efficacy of risankizumab
|
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:sampled_in |
1:1:1 ratio
|
| gptkbp:sponsor |
gptkb:Abb_Vie
|
| gptkbp:start_date |
2017-06-01
|
| gptkbp:status |
completed
|
| gptkbp:study_completion |
met primary endpoints
|
| gptkbp:study_design_type |
multicenter study
|
| gptkbp:study_findings |
support further development of risankizumab.
|
| gptkbp:study_results_publication |
peer-reviewed journals
|
| gptkbp:treatment_groups |
risankizumab, placebo, comparator
|
| gptkbp:trial_design |
randomized controlled trial
|
| gptkbp:vision |
double-blind
|
| gptkbp:year |
2020-12-01
|
| gptkbp:bfsParent |
gptkb:ixekizumab
gptkb:Ixekizumab |
| gptkbp:bfsLayer |
6
|